Phase 1 study of ABBV-400, a novel anti-Met antibody drug conjugate, in advanced solid tumors

Toshio Shimizu,John Powderly,Manish R. Sharma, Xiaowen Guan, Athanasios Vasilopoulos,Martha Li, Rui Li,Alexis Cunningham, Regina Reilly, Gladys Morrison-Thiele,Kevin Freise, Martha Neagu Aristide,D. Ross Camidge

ANNALS OF ONCOLOGY（2023）

引用 0|浏览1

暂无评分

摘要

Non-small cell lung cancers (NSCLCs), colorectal tumors, and gastric/gastroesophageal junction adenocarcinomas (GEA) frequently overexpress c-Met. The first-generation c-Met targeting antibody-drug conjugate carrying a monomethyl auristatin E payload, telisotuzumab vedotin (ABBV-399), recently received USDA Breakthrough Therapy Designation for nonsquamous, c-Met expressing NSCLC. The next-generation version, ABBV-400 uses a topoisomerase inhibitor payload.

查看译文

关键词

antibody,advanced solid tumors,drug conjugate,anti-met

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要